Dr. Romyr Dominique joined the TB Alliance as  Director of Medicinal Chemistry in January 2025. Prior to joining TB Alliance, Romyr gained valuable drug discovery experience at PMV Pharmaceuticals and Hoffmann-La Roche, where he worked for a combined total of 18 years. During his professional career, Romyr made significant contributions to several drug discovery projects across various therapeutic areas, including oncology, inflammation, metabolic diseases, and virology. More recently, Romyr was part of the team that discovered Rezatapopt, a first-in-class, small-molecule reactivator of the p53 Y220C mutant, which is currently in clinical trials for cancer patients.

Romyr received his undergraduate degree in biochemistry from the University of Montreal, his Ph.D. in organic chemistry from the University of Ottawa and completed his post-doctoral studies at Scripps Research Institute.